| 000 | 01693 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518093230.0 | ||
| 264 | 0 | _c20201217 | |
| 008 | 202012s 0 0 eng d | ||
| 022 | _a1872-7980 | ||
| 024 | 7 |
_a10.1016/j.canlet.2020.03.020 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Lun | |
| 245 | 0 | 0 |
_aMARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma. _h[electronic resource] |
| 260 |
_bCancer letters _c06 2020 |
||
| 300 |
_a29-38 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aAutophagy _xdrug effects |
| 650 | 0 | 4 |
_aBortezomib _xadministration & dosage |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aChloroquine _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 |
_aMicroRNAs _xgenetics |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 |
_aMyristoylated Alanine-Rich C Kinase Substrate _xantagonists & inhibitors |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aRastgoo, Nasrin | |
| 700 | 1 | _aWu, Jian | |
| 700 | 1 | _aZhang, Min | |
| 700 | 1 | _aPourabdollah, Maryam | |
| 700 | 1 | _aZacksenhaus, Eldad | |
| 700 | 1 | _aChen, Yan | |
| 700 | 1 | _aChang, Hong | |
| 773 | 0 |
_tCancer letters _gvol. 480 _gp. 29-38 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.canlet.2020.03.020 _zAvailable from publisher's website |
| 999 |
_c30788499 _d30788499 |
||